Cargando…

Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by (1)H-Magnetic Resonance Spectroscopy

Objective. The RNAFH study (effect of rosuvastatin on nonalcoholic fatty liver disease in metabolic syndrome patients without overt diabetes evaluated by (1)H-MRS) is a prospective randomized, single-center, open-label trail designed to assess the effect of rosuvastatin on the intrahepatocellular li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ping, Fan, Wang, Xuan, Yang, Jing, Zhou, Mei-cen, Li, Wei, Xu, Ling-ling, Li, Yu-xiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090105/ https://www.ncbi.nlm.nih.gov/pubmed/27872642 http://dx.doi.org/10.1155/2016/8454751

Ejemplares similares

Ferroptosis resistance cooperates with cellular senescence in the overt stage of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
por: Vetuschi, Antonella, et al.
Publicado: (2022)

Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients
por: Malaguarnera, Michele, et al.
Publicado: (2011)

Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes
por: Torimoto, Keiichi, et al.
Publicado: (2013)

Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus
por: Hwang, You-Cheol, et al.
Publicado: (2019)

Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy
por: Chan, Ruth, et al.
Publicado: (2015)

Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study
por: Fellström, Bengt, et al.
Publicado: (2005)

Comparison of the Efficacy of Rosuvastatin 5 mg and 10 mg in Patients of Type 2 Diabetes Mellitus With Dyslipidemia
por: Aleem, Mudassar, et al.
Publicado: (2022)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies
por: Robinson, Jennifer G., et al.
Publicado: (2014)

Functional near-infrared spectroscopy for the assessment of overt reading
por: Safi, Dima, et al.
Publicado: (2012)

Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)
por: Clearfield, Michael B, et al.
Publicado: (2006)

A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy
por: Strain, Joe D, et al.
Publicado: (2010)

Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2019)

Cortical signature of patients with HBV-related cirrhosis without overt hepatic encephalopathy: a morphometric analysis
por: Wu, Xiu, et al.
Publicado: (2015)

Progressive multifocal leukoencephalopathy without overt immunosuppression
por: Jain, Varun, et al.
Publicado: (2023)

Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9)
por: Sohn, Tae Seo
Publicado: (2019)

Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9)
por: Hwang, You-Cheol
Publicado: (2019)

Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease
por: Wang, Xin, et al.
Publicado: (2011)

Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention
por: Mouzaki, Marialena, et al.
Publicado: (2019)

Effect of Alirocumab and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaque in Coronary Artery Disease Seen on Near-Infrared Spectroscopy Intravascular Ultrasound (ANTARES)
por: Otake, Hiromasa, et al.
Publicado: (2019)

Rosuvastatin exerts cardioprotective effect in lipopolysaccharide-mediated injury of cardiomyocytes in an MG53-dependent manner
por: Zhuang, Jiawei, et al.
Publicado: (2022)

Effects of rosuvastatin and/or β-carotene on non-alcoholic fatty liver in rats
por: Seif el-Din, Sayed H., et al.
Publicado: (2015)

A Bioequivalence Study of Ezetimibe/Rosuvastatin Fixed Dose Combination (10 mg/10 mg) Versus the Individual Formulations Taken Concomitantly
por: Di, Yujing, et al.
Publicado: (2023)

The role of magnetic resonance elastography in the evaluation of nonalcoholic fatty liver disease
por: Idilman, Ilkay S., et al.
Publicado: (2023)

Rationale, design, and methods for the Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD) study
por: Berry, Diane C., et al.
Publicado: (2018)

Association Between Serum Afamin Levels with Nonalcoholic Associated Fatty Liver Disease
por: Chen, Shenghui, et al.
Publicado: (2022)

Resolving social conflict among females without overt aggression
por: Cant, Michael A., et al.
Publicado: (2013)

Limosilactobacillus fermentum MG4294 and Lactiplantibacillus plantarum MG5289 Ameliorates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced Mice
por: Lee, Ji Yeon, et al.
Publicado: (2023)

Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency
por: Viigimaa, Margus, et al.
Publicado: (2010)

Pharmacokinetics of fixed-dose combination of rosuvastatin 20 mg and ezetimibe 10 mg compared to concurrent administration of individual tablets in healthy Korean subjects
por: Hwang, Inyoung, et al.
Publicado: (2018)

Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction
por: Tunçez, Abdullah, et al.
Publicado: (2019)

Early decrease in carotid plaque lipid content as assessed by magnetic resonance imaging during treatment of rosuvastatin
por: Du, Ruixue, et al.
Publicado: (2014)

Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis—design, rationale, and methodology of the METEOR-China study
por: Wang, Yilong, et al.
Publicado: (2020)

Serum biomarkers combined with ultrasonography for early diagnosis of non-alcoholic fatty liver disease confirmed by magnetic resonance spectroscopy
por: Qian, Ling-ling, et al.
Publicado: (2019)

Coronary heart disease is associated with nonalcoholic fatty liver disease in patients without hypertension and diabetes
por: Liu, Zipeng, et al.
Publicado: (2020)

Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
por: Roggeri, Daniela Paola, et al.
Publicado: (2017)

Atrioventricular and Ventricular Functional Interdependence in Individuals Without Overt Cardiac Disease
por: Yoshida, Yuriko, et al.
Publicado: (2021)

Current Perspectives on rosuvastatin
por: Hu, Miao, et al.
Publicado: (2013)

Exercise without dietary changes alleviates nonalcoholic fatty liver disease without weight loss benefits
por: Ok, Duck-Pil, et al.
Publicado: (2018)

Classification of Overt and Covert Speech for Near-Infrared Spectroscopy-Based Brain Computer Interface
por: Kamavuako, Ernest Nlandu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ii1tcprqli485ch38j38e62jon